Complete range of best-in-class strategic services

We create value across the product life cycle, from pre-clinical stages, through phases I, II and III, to launch and beyond, and right up to LoE. Our complete range of best-in-class services are built on the bedrock of our long-established and superior competitive intelligence capabilities.

Launch Optimisation

From new product launches to label extensions, our comprehensive launch optimisation expertise considers how all external environmental factors can be taken into account to make your launch plan more effective.

It is absolutely vital to understand how competitors will seek to impede your launch and shape your market, especially by influencing key stakeholders, to create an unfavourable launch environment. Deallus excels at integrating the external competitive environment into your plan to strengthen working assumptions and provide increased confidence for a clearer path forward.

Deallus Stakeholder segmentation and growth strategy

Stakeholder segmentation and growth strategy

Mapping and segmenting influential stakeholders affecting the brand

Deallus Registration requirements and timelines

Registration requirements and timelines

Understanding registrations and post registration requirements and possibilities

Deallus Launch engagement strategies

Launch engagement strategies

Developing sustained insights into the evolving dynamics of key launch markets, to ensure alignment between global and local launch strategies

Competitor analysis

Mapping the competitor landscape whilst assessing biosimilar and generic threats

Deallus Pricing strategy

Pricing strategy

Mapping and analysing competitor pricing strategies to ensure strong strategic decision makings

Find out more

Launch optimisation related insight

All Deallus Insight

The Future of JAK Inhibitors

Categories: White Paper|Tags: , , |

From blockbuster drugs to black box warnings, Janus kinase inhibitors (JAKs) have seen dramatic highs and lows in their journey to market access across the last few years. Yet despite the hurdles, JAKs are facing, pharma’s conviction in their potential to generate a paradigm shift in patient care means R&D activity and interest remains undaunted. Will JAK inhibitors triumph over persisting regulatory roadblocks to offer patients a new treatment option? In this white paper, we investigate the current state of JAKs and explore their likelihood of success in the future.

Launching for Success

Categories: Case Study|Tags: , , , |

Our client was a small-to medium-sized pharmaceutical company with a limited development pipeline who was in the process of launching their first product, an orphan drug, for treating a rare disease. They were a relatively small organisation with no prior knowledge of the competitive environment and no standardised launch planning process or procedures. This case study explores how our client engaged us to help them understand their competitive landscape, streamline launch efforts across markets, and stress test and revise their launch planning strategies.

The Three A’s of Launch Readiness

Categories: White Paper|Tags: , , , |

Drug launch failures happen more frequently than pharma companies care to admit. Anticipate, Adapt and Align - the three A’s of successful pharma launch strategy. To understand and implement them requires strategic vision, a holistic understanding of every vagary of the marketplace, and a forthright and ruthlessly honest assessment of both the product being launched and the competitive space it is meant to occupy.

Opportunity and Threat Assessment

As markets become ever more complex and competition increases, the ability to properly assess opportunities and threats by truly understanding and exploiting the strategic intent of competitors is becoming more important than ever.

The service provided by Deallus strengthens your competitive strategy by revealing the hidden opportunities that exist behind market threats.

Deallus Market landscape assessment

Market landscape assessment

Therapy area landscaping to understand market dynamics and identify emerging technology and products

Deallus Treatment drivers exploration

Treatment drivers exploration

Mapping treatment decision drivers and how they change over time

Deallus Decision framework development

Decision framework development

Creating decision frameworks to cultivate tangible action plans for opportunities and threats

Deallus Product profile analysis

Product profile analysis

Developing a product profile founded upon a deep understanding of product value, positioning and patient segmentation

Competitor evaluation

Evaluating competitors based on enhanced awareness of commercial capabilities, behaviour, positioning, and R&D progressions

Deallus Market asset attractiveness

Market/asset attractiveness

Considering attractiveness for indication prioritisation, entry, and expansion

Find out more

Opportunity and threat assessment related insight

All Deallus Insight

Competitive Simulation Strategy

Categories: Case Study|Tags: , , , |

Our client was facing a major pharma player in a highly lucrative and rare disease space. They wanted to ensure that they had a chance to analyze their competition’s launch plan and plans for targeting their own product, but they did not have the time to conduct a cross-functional, traditional workshop. They came to us to discuss their goals and assess the most strategic way forward. This case study explores this launch scenario in which we put a unique spin on the traditional competitive simulation approach for our client.

Asia Market Entry

Categories: White Paper|Tags: , , |

A continent of extremes, with great potential for growth. Geographically large, the assortment of cultures, people, disease profiles, and healthcare systems added to the juxtaposition of extreme wealth and extreme poverty, emphasises the many challenges faced by the pharmaceutical companies when thinking of entering Asia. Commercial success will depend on understanding the market dynamics by consolidating positioning within the market place with the requirements of each market.

Asian Pricing and Reimbursement

Categories: White Paper|Tags: , , , |

Growing major trends are emerging across Asian healthcare markets. Rising incomes, increased government healthcare expenditure, higher life expectancies and a surge of chronic illnesses are boosting the demand for pharmaceutical products and services in the region. We take a look at the emerging trends across Asian healthcare systems and the implications for the industry.

Competitive Readiness

Our competitive readiness capabilities have established Deallus as a trusted partner to many of the world’s leading life sciences companies.

Our capability-building, based on the compelling competitor and market insights we unearth, underpins client strategic decision-making, reinforces competitive mindsets and strengthens brand planning processes to enhance competitive readiness across all relevant divisions, functions and geographies.

CI manager training

Integrating competitive intelligence and the management of CI within an organisation

Deallus Training the trainer

Training the trainer

Developing internal competitive intelligence champions to drive the value of CI throughout the organisation

Building a competitive mindset

Integrating competitive insights into meaningful brand planning

Deallus Training field teams

Training field teams

Sales force training centered on developing a competitive mindset and demystifying competitive challenges

Find out more

Competitive readiness related insight

All Deallus Insight

The Future of JAK Inhibitors

Categories: White Paper|Tags: , , |

From blockbuster drugs to black box warnings, Janus kinase inhibitors (JAKs) have seen dramatic highs and lows in their journey to market access across the last few years. Yet despite the hurdles, JAKs are facing, pharma’s conviction in their potential to generate a paradigm shift in patient care means R&D activity and interest remains undaunted. Will JAK inhibitors triumph over persisting regulatory roadblocks to offer patients a new treatment option? In this white paper, we investigate the current state of JAKs and explore their likelihood of success in the future.

Digitizing Healthcare

Categories: White Paper|Tags: , |

Healthcare has always had a reputation of being resistant to change, but consumer demand and a rapidly evolving technology-driven world have led the digitization of healthcare to move at a frantic pace. In this white paper we explore the digitization trend currently infiltrating healthcare and delve into the implications of digital health on patients, payers, and pharma itself. We take stock of the current landscape, discuss likely future trends, and explore how strategic intelligence can help answer key questions for the healthcare industry in the face of so much digital innovation.

Let’s talk about NASH

Categories: White Paper|Tags: , |

Several promising candidates are currently competing in a multi-billion-dollar race. NASH, or non-alcoholic steatohepatitis, affects millions of patients world-wide and by 2020 is projected to replace hepatitis C as the number one reason for liver transplantation in the United States. Multiple drug developers have taken on the challenge and a variety of different approaches are currently in the pipeline to tackle this complex, silent disease. Now all eyes are on the finish line to see who will be the first to enter this lucrative and untapped market.

Asset and Portfolio Management

Deallus’ comprehensive and in-depth approach to competitive asset and portfolio lifecycle management delivers the assurance you need to make the right decisions for your NME, acquired asset, or even for an entire portfolio or business unit.

By offering reliable and resourceful analytics on a wide range of interrelated issues, including R&D activities, in-licensing and M&A, therapeutic area targeting, portfolio and indication prioritisation, lifecycle and LoE planning, and more, Deallus partners with our clients to achieve optimised value for your investments and astute ROI insights to support and maximise the performance of commercial portfolios.

Deallus Therapeutic area and commercial prospecting

Therapeutic area and commercial prospecting

Identifying the competitive landscape in order to accurately inform therapy area and commercial prospects

Deallus LoE and Peri LoE planning

LoE and Peri LoE planning

Managing and prioritising assets within a portfolio to balance resources and maximise position within a therapeutic area

Building and optimising portfolios

Interpreting opportunities for partnership, co-promotion, co-marketing, and other investments whilst holistically assessing the product lifecycle to maximise potential

Asset and portfolio evolution

Incorporating technology assessments, payer trends, and more to understand how to establish and maintain portfolio relevance

Find out more

Asset and portfolio management related insight

All Deallus Insight

Asset Evaluation

Categories: Case Study|Tags: , , , , |

Our client was a medium-sized pharma company interested in launching an antibiotic asset for treating pathogens with limited treatment options in Central and Southern Europe, as well as the Middle East. Their antibiotic was a particularly strong candidate for commercialization due to its novelty in tackling multi-resistant antibiotic pathogens and the extremely high unmet demands in the targeted regions. Our client engaged us to work with their business intelligence managers in order to evaluate the commercial value of the asset and to advise on the best strategic route to commercialization.

Purchasing a Pipeline

Categories: White Paper|Tags: , , , |

Perils, pitfalls, and priorities in asset acquisition. In this White Paper, we will look at new and changing trends in pipeline acquisition, discuss difficulties inherent in the current marketplace, and offer worthwhile perspectives on pitfalls and opportunities based on our experience offering strategic guidance to pharmaceutical companies on a global scale.

Brand Decision Making

When operating in markets that are especially complicated or where competition is fierce, there is often a need to go beyond our Opportunity and Threat Assessment and explore core market dynamics to the deepest extent possible.

This allows the right brand decisions, in terms of brand and portfolio positioning, distinct and sustainable promotional strategy and messaging, and distinctive value propositions, to be made.

Deallus Map spheres of influence

Map spheres of influence

Mapping influencers to understand key stakeholders in a specific therapy area

Deallus Optimal promotional strategy development

Optimal promotional strategy development

Identifying promotional strategy options and courses of action for the brand

Benchmarking VoC dashboard

Developing company and brand performance metrics against competitors

Deallus Modelling growth through patients

Modelling growth through patients

Predicting growth and change to forecast brand opportunities

Brand and portfolio positioning

Assessing current and potential brand or portfolio positions as compared to competitors

Beyond the pill value added initiatives

Identifying the value added services that will resonate with key stakeholders

Find out more

Brand decision making related insight

All Deallus Insight

Copay Accumulator Programs & Pharma

Categories: White Paper|Tags: , , |

Dynamics between pharma and the market-based healthcare sector it serves have invariably been complex, with one of the biggest drivers of that complexity being effective management of patient demand and payer systems. The newest stratagem in this push and pull is the copay accumulator program, or CAP. We take a closer look at CAPs and how they might affect your brand in the near future.

Organisational Analysis

Our proven methodologies for analysing a broad spectrum of drivers helps safeguard the commercial effectiveness of your organisation against constantly evolving and ever-changing competitive market challenges.

Our class-leading expertise in analysing internal organisational and external market environments will help ensure your organisation is fit and healthy to meet any future strategic challenges.

Commercial effectiveness diagnostic

Analysing a broad spectrum of commercial effectiveness drivers and identifying competitive benchmarks, key market events, and risks

Channel preference analysis and multi-channel integration

Combining market research, social listening, and competitive intelligence to identify channel preferences

Deallus Customer engagement capability building

Customer engagement capability building

Training on advance engagement skills, with expertise in training and coaching cross-functional teams and embedding a competitive mindset

Deallus Organisation design

Organisation design

Analysing the competitive environment, customer needs, and internal capabilities to influence organisational design decisions

Deallus Social listening driving digital strategy

Social listening driving digital strategy

Utilising ‘live info’ to inform promotional tactics whilst evaluating competitors’ presence and strength across digital channels

Find out more

“Deallus was appointed to help us create a market access strategy when we were planning to enter a number of key emerging markets. The insights and analysis they provided equipped us with an in-depth understanding of the competitive landscape, key stakeholders, pricing and patient flow. On top of this they conceived an invaluable strategic roadmap for entry into each market. Deallus’ contribution was certainly outstanding as they helped us successfully drive access and uptake globally.”

Director of Global Market Access, Top 20 pharma brand